Elmagin Capital LLC v. Chao Chen

Court of Appeals for the Third Circuit·Decided June 5, 2024·No. 22-2739·Unpublished

Opinion

NOT PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

Nos. 22-2739, 22-2813, 22-2889 and 23-3104

ELMAGIN CAPITAL, LLC,

Appellant in Nos. 22-2739 and 22-2889

v.

CHAO CHEN; KARL PETTY; ENTERGRID, LLC;

ENTERGRID FUND I, LLC

Appellants in Nos. 22-2813 and 23-3104

On Appeal from the United States District Court For the Eastern District of Pennsylvania (D.C. No. 2-20-cv-2576)

Circuit Judge: Honorable Stephanos Bibas*

Submitted Under Third Circuit L.A.R. 34.1(a)

November 3, 2023

Before: JORDAN, ROTH., and AMBRO, Circuit Judges

(Filed March 21, 2024 )

OPINION

*

The Honorable Stephanos Bibas, Circuit Judge sitting by designation pursuant to 28 U.S.C. § 291(b).

 This disposition is not an opinion of the full court and, pursuant to I.O.P. 5.7, does not constitute binding precedent.

JORDAN, Circuit Judge.

Elmagin Capital, LLC appeals the District Court’s denial of motions for judgment as a matter of law and a new trial for breach of contract and trade secret misappropriation. Chao Chen cross-appeals the District Court’s denial of his request for attorneys’ fees. For the following reasons, we will affirm. I. BACKGROUND In 2014, brothers Richard and Kevin Gates joined with Chao Chen to found Elmagin Capital, LLC. It was established to trade in financial transmission rights (“FTRs”) in wholesale electricity markets.1 Chen developed trading strategies for Elmagin. During his tenure at Elmagin, he developed or participated in developing the two trading strategies still at issue in this case, one called “Breck,” and another called “Faber.” 2 While at Elmagin, Chen engaged defendant Karl Petty as a consultant to provide historical data analysis services. Before doing any work for Elmagin, Petty signed a

Consulting Agreement that prohibited him from using, exploiting, or disclosing Elmagin’s “confidential information.” In 2016, Chen informed the Gates brothers that he wished to leave Elmagin. The Gates brothers purchased Chen’s share in Elmagin, and Chen signed a Non-Disclosure and Non-Competition Agreement (“NDA”) that prohibited him from engaging in a competing business for one year and from ever using, exploiting, or disclosing Elmagin’s confidential information, including its trading strategies. Chen left Elmagin in January 2018.

In January 2019, he formed Entergrid, LLC and Entergrid Fund I, LLC for the purpose of trading in FTRs in wholesale electricity markets. He developed FTR trading strategies, including the allegedly misappropriating strategies, “Hydra” and “Gryphon.” Petty joined Entergrid in the spring of 2019. Chen taught Petty the basics of power markets and FTRs, and Petty kept notes.

Elmagin sued Chen, Petty and Entergrid in District Court, accusing them of disclosing and using the Breck and Faber strategies in violation of the NDA and the Defend Trade Secrets Act (“DTSA”), 18 U.S.C. § 1836, et seq., as well as Pennsylvania’s Uniform Trade Secrets Act (“PUTSA”), 12 Pa. Cons. Stat. § 5302, et seq. Chen responded that he only shared public information, that Breck and Faber combined well- known elements, and that his trading strategies were different from Elmagin’s.

The case went to trial in May of 2022. The jury found that the Breck and Faber strategies were trade secrets, but that Chen did not use them to develop Hydra and Gryphon. Chen accused Elmagin of bringing the suit in bad faith and asked the District Court for attorneys’ fees. The Court sent that question to the jury, and the jury found bad

faith, but the Court considered the jury’s answer advisory and declined to award attorneys’ fees. The Court also denied Elmagin’s motions for judgment as a matter of law and a new trial. The parties’ cross appeals followed. II. DISCUSSION3 A. The Misappropriation Claim To prevail on a claim for misappropriation of trade secrets under both the DTSA and the PUTSA, a plaintiff must establish (1) the existence of a trade secret, (2) that the trade secret was protectible, and (3) that it was misappropriated by the defendant. 18 U.S.C. §§ 1836(b)(1), 1839(3), (5); 12 Pa. Cons. Stat. § 5302.4 A trade secret may be a business method as long as it has “independent economic value” and “the owner … has taken reasonable measures to keep [it a] secret.” 18 U.S.C. § 1839(3); Oakwood Labs.

LLC v. Thanoo, 999 F.3d 892, 905 (3d Cir. 2021). The plaintiff must define his trade secret “with sufficient particularity … to permit the defendant to ascertain … the boundaries within which the secret lies.” Id. at 906. Trade secret law does not protect “general knowledge in the trade or … special knowledge of those persons who are skilled in the trade.” Id.

Misappropriation encompasses “disclosure or use of a trade secret” without consent, including “relying on the trade secret to assist or accelerate research or development[.]” 18 U.S.C. § 1839(5)(B); 12 Pa. Cons. Stat. § 5302; Oakwood, 999 F.3d at 909. Rarely can a plaintiff demonstrate misappropriation through direct evidence. Oakwood, 999 F.3d at 913. Instead, a plaintiff may rely on circumstantial evidence of access to the trade secrets and similarity between the secrets and the accused product. Id. at 909 n.18. But when public information and the defendant’s own knowledge, uninformed by the trade secret, effectively confine the scope of the trade secret, “more than … similarity” may be needed to prove misappropriation. Am. Can Co. v. Mansukhani, 742 F.2d 314, 331 (7th Cir. 1984); cf. Oakwood, 999 F.3d at 912 n.19 (suggesting a “plus factor” may be helpful when relying on circumstantial evidence).

At trial, Elmagin claimed that Hydra copied aspects of Breck, and Gryphon copied aspects of Faber. The jury was instructed to “assess whether the whole strategy, as opposed to its individual steps” warranted trade secret protection. (J.A. at 1526.) The jury found that both Faber and Breck constituted trade secrets. The jury was instructed to find misappropriation if the defendants, among other things, had access to the strategies

and if the strategies were “similar enough.” (J.A. at 1527-28.) They held that Chen, Petty, and Entergrid did not misappropriate the Breck and Faber strategies.

On appeal, Elmagin asks for a new trial or judgment as a matter of law on its claim that Hydra represents a misappropriation of Breck and a breach of the NDA. It also says that a new trial on all its claims is warranted because, in its view, the District Court erroneously permitted Chen’s prejudicial and irrelevant expert testimony.

1. The jury reasonably found that Hydra did not constitute a misappropriation of Breck.

Elmagin contends that the jury accepted its trade secret theory regarding Breck and that no evidence supported their finding regarding no misappropriation. Defining Breck, as it does, at a high level of abstraction and ignoring implementation details, Elmagin claims that Hydra is similar to Breck. But Elmagin cannot claim that the implementation details are irrelevant when it used them to defeat summary judgment and presented them to the jury at trial. Cf. Amazon.com, Inc. v. Barnesandnoble.com, Inc., 239 F.3d 1343, 1351 (Fed. Cir. 2001) (“A patent may not, like a ‘nose of wax,’ be twisted one way [for validity] and another to find infringement.”).

Free access — add to your briefcase to read the full text and ask questions with AI

Elmagin Capital LLC v. Chao Chen, (3d Cir. 2024).

Elmagin Capital LLC v. Chao Chen (Elmagin Capital LLC v. Chao Chen) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related